Haldol Decanoate

Haldol Decanoate is a long‑acting intramuscular injection containing the active ingredient haloperidol decanoate. It is a prescription‑only antipsychotic medication classified as a butyrophenone and is marketed in the European Union. The formulation is designed for depot administration, providing sustained dopamine D2 receptor antagonism over several weeks to support the management of psychotic disorders.

Haldol Decanoate is indicated for the treatment of schizophrenia and related psychotic conditions, particularly when stable maintenance therapy is required. It may also be employed in acute psychosis when rapid symptom control is needed.

- Maintenance treatment of schizophrenia to reduce relapse risk - Acute psychotic episodes requiring injectable therapy - Adjunctive therapy for patients with poor oral medication adherence - Long‑term management of chronic psychotic disorders - Situations where a depot formulation is preferred over daily oral dosing

Side effects of Haldol Decanoate can vary in frequency and severity. Patients should be monitored for both common and serious reactions.

Common: - Drowsiness or sedation - Extrapyramidal symptoms such as tremor or rigidity - Weight gain or increased appetite - Dry mouth - Constipation - Orthostatic hypotension

Serious: - Neuroleptic malignant syndrome - Tardive dyskinesia - Severe hypotension or cardiac arrhythmias - Hyperprolactinemia with galactorrhea - Seizures in susceptible individuals

Before initiating Haldol Decanoate, clinicians should evaluate several safety considerations. The medication requires careful monitoring in specific patient populations.

- Assess cardiovascular status, especially in patients with known heart disease - Monitor for signs of extrapyramidal symptoms and tardive dyskinesia - Evaluate liver and kidney function periodically - Use caution in patients with a history of seizures or neuroleptic malignant syndrome - Discuss pregnancy and lactation risks, as safety data are limited - Review any history of substance abuse or non‑adherence to treatment

Haldol Decanoate may interact with other drugs, influencing its efficacy or safety profile. Some combinations should be avoided, while others require careful monitoring.

Avoid: - Other dopamine antagonists or high‑potency antipsychotics - Medications that prolong QT interval (e.g., certain antiarrhythmics, macrolide antibiotics) - Strong CYP3A4 inhibitors that could increase haloperidol levels

Use with caution: - CNS depressants such as benzodiazepines or opioids - Anticholinergic agents used to manage extrapyramidal symptoms - Drugs that affect electrolyte balance (e.g., diuretics) - Medications that may lower seizure threshold